Difficulty: Medium
Average Score: 85%
Practice
This drug is associated with Torsades de pointes:
Correct answer
B
Rationale
The correct answer is B) Sotalol. Sotalol is a non-selective beta-blocker that also possesses Class III antiarrhythmic properties. It prolongs the QT interval, which can predispose patients to developing Torsades de pointes, a potentially life-threatening polymorphic ventricular tachycardia.
Option A) Flecainide is a Class IC antiarrhythmic drug that does not significantly prolong the QT interval and is not typically associated with Torsades de pointes.
Option C) Lidocaine is a Class IB antiarrhythmic drug that also does not prolong the QT interval and is not linked to Torsades de pointes.
Option D) Verapamil is a calcium channel blocker that does not have significant effects on the QT interval and is not commonly associated with Torsades de pointes.
In an educational context, understanding the association between certain drugs and Torsades de pointes is crucial for healthcare professionals, especially those working in cardiology or critical care settings. Knowing which medications can potentially lead to this dangerous arrhythmia enables healthcare providers to monitor patients appropriately, recognize early signs of QT prolongation, and take necessary precautions to prevent adverse outcomes.
Option A) Flecainide is a Class IC antiarrhythmic drug that does not significantly prolong the QT interval and is not typically associated with Torsades de pointes.
Option C) Lidocaine is a Class IB antiarrhythmic drug that also does not prolong the QT interval and is not linked to Torsades de pointes.
Option D) Verapamil is a calcium channel blocker that does not have significant effects on the QT interval and is not commonly associated with Torsades de pointes.
In an educational context, understanding the association between certain drugs and Torsades de pointes is crucial for healthcare professionals, especially those working in cardiology or critical care settings. Knowing which medications can potentially lead to this dangerous arrhythmia enables healthcare providers to monitor patients appropriately, recognize early signs of QT prolongation, and take necessary precautions to prevent adverse outcomes.